TOLAK UKUR FUNGSI HATI BERDASARKAN DERAJAT FIBROSIS PENYAKIT HATI KRONIS (Liver Function Parameters based on Degree of Liver Fibrosis in Chronic Liver Disease)

Evaluating the degree of liver fibrosis degree is invasive as well as uncomfortable, therefore, non invasive examinations such as liverfunction tests and elastography (Fibro Scan) as a predictor‘s device of liver fibrosis degree are necessary. The aim of this study was toknow the differences of liver function parameters based on the fibrosis degree in patients with chronic liver disease. This study was a crosssectional design using data from chronic liver disease patients treated at the Dr. Wahidin Sudirohusodo Hospital. The elasticity of the liverwas measured using a fibro scan device during June 2010–July 2011. The analysis was carried out by ANOVA test on various parametersof liver function particularly on the fibrosis degree in chronic liver disease. In this study PT, albumin, total bilirubin and platelet countshowed a significant difference of 0.019, 0.009, 0.017 and 0.000 respectively. The mean values of PT and total bilirubin were significantlyhigher in the high degree of fibrosis compared to those with medium and low degree of fibrosis in the chronic liver disease patients. Basedon this study, the mean albumin levels and platelet count were significantly lower in the high degree of fibrosis compared with the mediumand low degree of fibrosis, however, no significant differences in AST, ALT, APTT and GGT were found.

Download Full-text

Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease.

Clinical Chemistry ◽

10.1093/clinchem/30.2.211 ◽

1984 ◽

Vol 30 (2) ◽

pp. 211-215 ◽

Cited By ~ 74

Author(s):

I Myara ◽

A Myara ◽

M Mangeot ◽

M Fabre ◽

C Charpentier ◽

...

Keyword(s):

Alkaline Phosphatase ◽

Liver Disease ◽

Chronic Liver Disease ◽

Total Bilirubin ◽

Early Stage ◽

Chronic Liver ◽

Easy Method ◽

Prolidase Activity ◽

Ccl4 Administration ◽

The Mean

Abstract We describe here an easy method of determining prolidase (EC 3.4.13.9) in plasma after preincubation with Mn2+ for 24 h at 37 degrees C to maximize prolidase activity. The mean activity in 338 patients who were either in hospital or outpatients was 900 U/L +/- 520 (2 SD), unrelated to sex or age. In 25 of these 338 samples tested, prolidase activity was between 1500 and 2000 U/L. It exceeded 2000 U/L in eight, all of whom were patients with chronic liver disease. Plasma prolidase activity was normal in cytolytic syndromes such as liver or heart disease. Of the 27 patients with cirrhosis, only five exhibited prolidase activity greater than 2000 U/L. Plasma prolidase activity was uncorrelated with six biochemical indexes to liver function (the aminotransferases, alkaline phosphatase, glutamyltransferase, total bilirubin, and serum albumin) or with the degree of cirrhotic fibrosis. We believe that plasma prolidase activity may be high only in the early stage of fibrosis. This hypothesis would be consistent with the data on rat-liver collagenolytic activities during CCl4 administration. Monitoring of plasma prolidase activity might be useful in evaluating fibrotic processes in chronic liver disease in the human.

Download Full-text

The validity of Triggering Receptor Expressed on Myeloid Cells (TREM-1) in diagnosis of Spontaneous Bacterial Peritonitis in cirrhotic patients

QJM ◽

10.1093/qjmed/hcaa069.001 ◽

2020 ◽

Vol 113 (Supplement_1) ◽

Author(s):

W Abdelmonsef ◽

N A Abdelkader ◽

G A Ismail ◽

M M Elgaafary ◽

Y A Abdelrazek

Keyword(s):

Liver Disease ◽

Chronic Liver Disease ◽

Ascitic Fluid ◽

Spontaneous Bacterial Peritonitis ◽

Chronic Liver ◽

Statistical Significant Difference ◽

Bacterial Peritonitis ◽

Significant Difference ◽

Cirrhotic Patients ◽

The Mean

Abstract Background Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients with ascites. Without early antibiotic treatment, this complication is associated with a 30-50% mortality rate. Recently we have evaluated the validity and utility of ascitic fluid triggering receptors expressed on myeloid cells-1 (TREM-1) levels for the diagnosis of SBP. Patients and Methods This was a Prospective case control study conducted on 60 patients with chronic liver disease and ascites divided into two group, group 1 (control) 30 patients without SBP and group 2 (SBP) 30 patients, admitted to the Tropical Medicine Department with ascites due to chronic liver disease. All patients were subjected to full history taking and clinical examination full laboratory investigations including complete blood picture liver and renal profiles, C reactive protein, viral markers, abdominal ultrasound, UGI endoscopy and ascitic fluid sampling for biochemical testing, total and differential cell count, microbiological culture and TREM-1 level. Results There was high statistical significant difference between the two groups in the base level of TREM-1 in which the mean was 1280 pg/ml (1136.9) with level range between (580---4500pg/ml) in SBP versus mean 129.9 pg/ml (51.9) with level range between (60-250pg/ml) in the control group. Also there was a statistical significant difference in the level of TREM-1 before and after treatment in the SBP patients in which the mean of TREM-1 before treatment was 1280.6 pg/ml (1136.9) with level range between (580-4500pg/ml) versus mean 376.2 pg/ml (78.4) and level range between (260-560 pg/ml) after the treatment. Conclusion our data indicate that the measurement of ascitic fluid TREM-1 is rapid, easy and valid test in the diagnosis and follow up of chronic liver disease patients with SBP.

Download Full-text

PERBANDINGAN PEMERIKSAAN TRIGLISERIDA METODE GLYCEROL BLANKING DAN NON GLYCEROL BLANKING PADA SIROSIS HEPATIS

INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY ◽

10.24293/ijcpml.v19i1.393 ◽

2016 ◽

Vol 19 (1) ◽

pp. 14

Author(s):

Sri Widyaningsih ◽

Leonita Anniwati ◽

Juli Soemarsono

Keyword(s):

Liver Cirrhosis ◽

Liver Disease ◽

Chronic Liver Disease ◽

Medical System ◽

Chronic Liver ◽

Free Glycerol ◽

Significant Difference ◽

The Mean ◽

Healthy Persons

Liver cirrhosis is a chronic liver disease with fibrosis and impairment of function. In liver disease increasing endogenous free glycerol has been found which constitutes a source of interference in the measurement of (TG). The aim of this study is to compare the glycerol blanking (TG-GB) which does not interfere with endogenous free glycerol to non glycerol blanking (TG-NGB) method in measuring TG in liver cirrhosis patients. In this study, sera were obtained from 22 liver cirrhosis and 30 healthy persons. All sera were measured for TG using TMS 1024i (Tokyo Boeki Medical System) with glycerol blanking (TG-GB) to non glycerol blanking (TG-NGB) method. In addition to this study, measurement of free glycerol was also compared to difference calculated TG-NGB and TG-GB in liver cirrhosis patients. The mean of TG-GB and TG-NGB measurements from healthy persons was 115.30±70.35 mg/dL and 121.27±67.14 mg/dL (p=0.108), respectively. The mean of TG-GB and TG-NGB measurements from liver cirrhosis patients was 101.09± 78,55 mg/dL and 120.91±79.44 mg/dL (p<0.0001). There was a significant difference between TG-GB and TG-NGB, and there was no significant difference between measurement of free glycerol to difference calculated TG-NGB and TG-GB in liver cirrhosis (p=0.784). However, there was a significant correlation between TG-GB and TG-NGB in healthy persons and liver cirrhosis patients. (p<0.0001). The measurement of TG-GB is more accurate than TG-NGB method in liver cirrhosis patients.

Download Full-text

Growth differentiation factor (GDF) -15– a novel biomarker to assess the extent of liver fibrosis in patients with chronic liver disease?

Zeitschrift für Gastroenterologie ◽

10.1055/s-0029-1191796 ◽

2009 ◽

Vol 47 (01) ◽

Cited By ~ 1

Author(s):

T Rädle-Hurst ◽

E Herrmann ◽

G Hess ◽

S Zeuzem ◽

F Lammert ◽

...

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Chronic Liver Disease ◽

Chronic Liver ◽

Differentiation Factor

Download Full-text

Mac‐2 Binding Protein Glycan Isomer as non‐invasive tool to assess liver fibrosis in children with chronic liver disease

Hepatology Research ◽

10.1111/hepr.13608 ◽

2021 ◽

Author(s):

Ola G Behairy ◽

Soha A El‐Gendy ◽

Dalia Y Ibrahim ◽

Amira I Mansour ◽

Ola S El‐Shimi

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Chronic Liver Disease ◽

Binding Protein ◽

Chronic Liver ◽

Non Invasive

Download Full-text

Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients

Therapeutic Advances in Gastroenterology ◽

10.1177/17562848211023410 ◽

2021 ◽

Vol 14 ◽

pp. 175628482110234

Author(s):

Mario Romero-Cristóbal ◽

Ana Clemente-Sánchez ◽

Patricia Piñeiro ◽

Jamil Cedeño ◽

Laura Rayón ◽

...

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Liver Injury ◽

Chronic Liver Disease ◽

Critically Ill ◽

Cox Regression ◽

Chronic Liver ◽

Cox Regression Analysis ◽

Risk Of Death ◽

The Impact

Background: Coronavirus disease (COVID-19) with acute respiratory distress syndrome is a life-threatening condition. A previous diagnosis of chronic liver disease is associated with poorer outcomes. Nevertheless, the impact of silent liver injury has not been investigated. We aimed to explore the association of pre-admission liver fibrosis indices with the prognosis of critically ill COVID-19 patients. Methods: The work presented was an observational study in 214 patients with COVID-19 consecutively admitted to the intensive care unit (ICU). Pre-admission liver fibrosis indices were calculated. In-hospital mortality and predictive factors were explored with Kaplan–Meier and Cox regression analysis. Results: The mean age was 59.58 (13.79) years; 16 patients (7.48%) had previously recognised chronic liver disease. Up to 78.84% of patients according to Forns, and 45.76% according to FIB-4, had more than minimal fibrosis. Fibrosis indices were higher in non-survivors [Forns: 6.04 (1.42) versus 4.99 (1.58), p < 0.001; FIB-4: 1.77 (1.17) versus 1.41 (0.91), p = 0.020)], but no differences were found in liver biochemistry parameters. Patients with any degree of fibrosis either by Forns or FIB-4 had a higher mortality, which increased according to the severity of fibrosis ( p < 0.05 for both indexes). Both Forns [HR 1.41 (1.11–1.81); p = 0.006] and FIB-4 [HR 1.31 (0.99–1.72); p = 0.051] were independently related to survival after adjusting for the Charlson comorbidity index, APACHE II, and ferritin. Conclusion: Unrecognised liver fibrosis, assessed by serological tests prior to admission, is independently associated with a higher risk of death in patients with severe COVID-19 admitted to the ICU.

Download Full-text

Chronic liver disease not a significant comorbid condition for COVID-19

Scientific Reports ◽

10.1038/s41598-021-91238-8 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Jiahao Lin ◽

Bingting Bao ◽

Nigar Anjuman Khurram ◽

Kasey Halsey ◽

Ji Whae Choi ◽

...

Keyword(s):

Liver Disease ◽

Liver Injury ◽

Chronic Liver Disease ◽

The United States ◽

Postmortem Examination ◽

Chronic Liver ◽

Critical Groups ◽

Comorbid Condition ◽

Central Vein ◽

Significant Difference

AbstractTo explore the role of chronic liver disease (CLD) in COVID-19. A total of 1439 consecutively hospitalized patients with COVID-19 from one large medical center in the United States from March 16, 2020 to April 23, 2020 were retrospectively identified. Clinical characteristics and outcomes were compared between patients with and without CLD. Postmortem examination of liver in 8 critically ill COVID-19 patients was performed. There was no significant difference in the incidence of CLD between critical and non-critical groups (4.1% vs 2.9%, p = 0.259), or COVID-19 related liver injury between patients with and without CLD (65.7% vs 49.7%, p = 0.065). Postmortem examination of liver demonstrated mild liver injury associated central vein outflow obstruction and minimal to moderate portal lymphocytic infiltrate without evidence of CLD. Patients with CLD were not associated with a higher risk of liver injury or critical/fatal outcomes. CLD was not a significant comorbid condition for COVID-19.

Download Full-text